Omeprazole 20Mg X8 Capsules

inhibits acid secretion in the stomach. It binds to the proton pump in the gastric parietal cell, inhibiting the final transport of H ⁺ into the gastric lumen.

ads.: tto. and prevention of recurrences of duodenal and gastric ulcers, eradication of H. pylori in peptic ulcers associated with adequate antibiotics, tto. gastric and duodenal ulcers associated with NSAIDs and their prevention in patients at risk, tto. reflux esophagitis, long-term control of healed GERD, tto. Symptomatic GERD, tto. yes Zollinger-Ellison. Children > 1 year old and pc ≥ 10 kg: tto. reflux esophagitis, tto. symptomatic of heartburn and acid regurgitation of GERD; children > 4 years: associated with antibiotics tto. H. pylori duodenal ulcer.

a) Ads., oral:
– Duodenal ulcer: 20 mg once/day, 2-4 weeks; poor response: 40 mg once/day, 4 weeks. Recurrence prevention: 20 mg once/day, increase to 40 mg once/day if necessary.
– Gastric ulcer: 20 mg 1 time/day, 4-8 weeks; poor response: 40 mg once/day, 8 weeks. Recurrence prevention: 20 mg once/day, increase to 40 mg once/day if necessary. – Gastric and duodenal ulcer associated with NSAIDs: 20 mg once/day, 4-8 weeks. Prevention in patients at risk (> 60 years, history of gastric or duodenal ulcer or upper gastrointestinal bleeding): 20 mg 1 time/day. – Reflux esophagitis: 20 mg 1 time/day, 4-8 weeks; severe: 40 mg 1 time/day. Maintenance of healed reflux esophagitis: 10 mg once/day (if necessary, increase to 20 or 40 mg once/day).
– Eradication of H. pylori in peptic ulcer: 20 mg omeprazole + 1 g amoxicillin + 500 mg clarithromycin 2 times/day or 20 mg omeprazole + 250 mg clarithromycin (or alternatively 500 mg) + 400 mg metronidazole (or 500 mg or 500 mg tinidazole) 2 times/day or omeprazole 40 mg once/day + amoxicillin 500 mg 3 times/day + metronidazole 400 mg (or tinidazole 500 mg or 500 mg) 3 times/day.- Treatment Symptomatic GERD: 10-20 mg/day. Evaluate again if after tto. 20 mg/day 4 weeks no control.
– S. Zollinger-Ellison: initial, 60 mg/24 h; then adjust between 20-120 mg/day; if it is > 80 mg/day, divide and administer /12 h.
perfume. IV 20-30 min: 40 mg once/day. S. Zollinger-Ellison, initial 60 mg/day, then adjust individually; if it is > 60 mg/24 h, divide and administer twice a day.
b) Children, oral:
– Treatment. reflux esophagitis. Children ≥ 1 year and pc 10-20 kg: 10 mg once/day (if necessary 20 mg once/day); children ≥ 2 years and ww > 20 kg: 20 mg once/day (if necessary 40 mg once/day), 4-8 weeks.
– Treatment symptomatic of heartburn and acid regurgitation in GERD. Children ≥ 1 year and pc 10-20 kg: 10 mg once/day (if necessary 20 mg once/day); children ≥ 2 years and bw > 20 kg: 20 mg once/day (if necessary 40 mg once/day), 2-4 weeks.
– Treatment H. pylori-associated duodenal ulcer, triple therapy (7-14 days), children > 4 years and adolescents: with 15-30 kg bw: 10 mg omeprazole + 25 mg/kg amoxicillin + 7.5 mg/kg clarithromycin 2 times /day, 1 week; with pc 31-40 kg: 20 mg omeprazole + 750 mg amoxicillin + 7.5 mg/kg clarithromycin 2 times/day, 1 week; with bw > 40 kg: 20 mg omeprazole + 1 g amoxicillin + 500 mg clarithromycin 2 times/day, 1 week.
HI: 10-20 mg/day.

N/A

hypersensitivity to omeprazole, benzimidazoles. Concomitance with nelfinavir.

HI not to exceed 20 mg/day, with severe HI periodic monitoring of liver enzymes. Rule out malignant lesion. May increase the risk of gastrointestinal infection (Salmonella and Campylobacter). Association with: clopidogrel, atazanavir is not recommended (if necessary, monitor symptoms and increase the atazanavir dose to 400 mg + 100 mg ritonavir). Reduces absorption of vit. B12 _{_}.Children: avoid tto. long term with disease chronic, IV limited experience. Regular surveillance in tto. > 1 year. Risk of hypomagnesemia in tto. prolonged and concomitant with digoxin or other drugs that can reduce the plasma level of Mg (eg diuretics); consider plasma Mg monitoring at the start and periodically during treatment. At high doses and in tto. prolonged, increases the risk of fracture of the hip, wrist and spine, especially in the elderly or in the presence of other risk factors, ensure intake of Ca and vit. D if there is a risk of osteoporosis. Do not take as preventive medication. Risk of subacute cutaneous lupus erythematosus (SCLE) (if lesions occur, especially in sun-exposed skin areas, accompanied by arthralgia, consider stopping treatment).

Caution, dosage: 10-20 mg/day. With severe IH, periodic monitoring of liver enzymes.

see Cont. and Price. In addition:
Reduces absorption of: ketoconazole, itraconazole, posaconazole, erlotinib (avoid concomitance with the last 2).
Increases systemic exposure of: active ingredients metabolized by CYP2C19 such as warfarin and other antagonists of vit. K, cilostazol, diazepam, phenytoin (monitor phenytoin concentration 2 1 ^as wk).
Check plasma level of: cyclosporine.
Inhibits hepatic metabolism of: triazolam, flurazepam and disulfiram.
Increases serum concentration of: tacrolimus (monitor renal concentration and function, adjust tacrolimus dose if necessary), methotrexate (temporarily withdraw omeprazole), saquinavir.
Serum concentration increased by: voriconazole, clarithromycin; consider dose adjustment in HI and in tto. dragged on.
Serum concentration decreased by: rifampicin, hypericum.
Increases bioavailability of: digoxin (caution in the elderly and monitor).

The results of three prospective epidemiological studies (including pregnancy outcomes of more than 1,000 exposed women) show no adverse effects of omeprazole on pregnancy or the health of the fetus or newborn. Omeprazole can be used during pregnancy.

Omeprazole is excreted in breast milk but is not likely to affect the child when therapeutic doses are used.

headache; abdominal pain, constipation, diarrhea, flatulence, nausea/vomiting; benign gastric polyps.